Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.
Fouad Y, Palmer M, Chen M, Regev A, Banerjee R, Myers R, Riccio R, Torstenson R, Younes R, Arora PS, Landgren H, Karsdal MA, Blake M, Shapiro DA, Gruss HJ, Sheikh MY, Attia D, Bollipo S, Smith AD, Freilich B, Gish RG, Schuppan D. Fouad Y, et al. Among authors: regev a. J Clin Transl Hepatol. 2022 Apr 28;10(2):374-382. doi: 10.14218/JCTH.2021.00408. Epub 2021 Oct 22. J Clin Transl Hepatol. 2022. PMID: 35528969 Free PMC article. Review.
Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.
Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Palmer M, et al. Among authors: regev a. Aliment Pharmacol Ther. 2020 Jan;51(1):90-109. doi: 10.1111/apt.15579. Epub 2019 Nov 25. Aliment Pharmacol Ther. 2020. PMID: 31762074 Free PMC article. Review.
Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.
Noureddin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N; Liver Forum NASH Cirrhosis Working Group. Noureddin M, et al. Gastroenterology. 2020 Aug;159(2):422-427.e1. doi: 10.1053/j.gastro.2020.04.039. Epub 2020 Apr 27. Gastroenterology. 2020. PMID: 32353369 No abstract available.
Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.
Fettiplace A, Marcinak J, Merz M, Zhang HT, Kikuchi L, Regev A, Palmer M, Rockey D, Fontana R, Hayashi PH, Tillmann HL, Di Bisceglie AM, Lewis JH. Fettiplace A, et al. Among authors: regev a. Aliment Pharmacol Ther. 2024 Nov;60(10):1293-1307. doi: 10.1111/apt.18271. Epub 2024 Sep 19. Aliment Pharmacol Ther. 2024. PMID: 39300766 Review.
Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis.
Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Treem WR, et al. Among authors: regev a. Drug Saf. 2021 Feb;44(2):133-165. doi: 10.1007/s40264-020-01014-2. Epub 2020 Nov 3. Drug Saf. 2021. PMID: 33141341 Free PMC article. Review.
Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum.
Palmer M, Kleiner DE, Goodman Z, Brunt E, Avigan MI, Regev A, Hayashi PH, Lewis JH, Mehta R, Harrison SA, Siciliano M, McWherter CA, Vuppalanchi R, Behling C, Miller V, Chalasani N, Sanyal AJ. Palmer M, et al. Among authors: regev a. Aliment Pharmacol Ther. 2024 Jan;59(2):201-216. doi: 10.1111/apt.17762. Epub 2023 Oct 25. Aliment Pharmacol Ther. 2024. PMID: 37877759
Drug rechallenge following drug-induced liver injury.
Hunt CM, Papay JI, Stanulovic V, Regev A. Hunt CM, et al. Among authors: regev a. Hepatology. 2017 Aug;66(2):646-654. doi: 10.1002/hep.29152. Epub 2017 Jun 26. Hepatology. 2017. PMID: 28295448 Review.
Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis.
Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N. Regev A, et al. Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153. Epub 2019 Feb 13. Aliment Pharmacol Ther. 2019. PMID: 30761572 Free PMC article. Review.
Epithelioid hemangioendothelioma of the liver.
Mindikoglu AL, Regev A, Schiff ER. Mindikoglu AL, et al. Among authors: regev a. Clin Gastroenterol Hepatol. 2005 Jul;3(7):xxxii. doi: 10.1016/s1542-3565(05)00361-7. Clin Gastroenterol Hepatol. 2005. PMID: 16206490 No abstract available.
627 results